94038-26-3

Basic information

• Product Name: 4-(4-BENZYL-PIPERAZIN-1-YL)-BENZOIC ACID
• Synonyms: AKOS BB-5317;4-(4-BENZYL-PIPERAZIN-1-YL)-BENZOIC ACID;RARECHEM AL BE 1230;4-(4-Benzyl-1-piperazinyl)benzoic acid
• CAS NO: 94038-26-3
• Molecular Formula: C₁₈H₂₀N₂O₂
• Molecular Weight: 296.36
• Mol File: 94038-26-3.mol

Chemical Properties

• Boiling Point: 482.4°C at 760 mmHg
• Flash Point: 245.5°C
• Appearance: /
• Density: 1.216g/cm³
• Vapor Pressure: 4.08E-10mmHg at 25°C
• Refractive Index: 1.625
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-(4-BENZYL-PIPERAZIN-1-YL)-BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-BENZYL-PIPERAZIN-1-YL)-BENZOIC ACID(94038-26-3)
• EPA Substance Registry System: 4-(4-BENZYL-PIPERAZIN-1-YL)-BENZOIC ACID(94038-26-3)

Safety Data

• Hazardous Substances Data: 94038-26-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
4-(4-Benzyl-piperazin-1-yl)-benzoic acid is used as a research tool for the development of new pharmaceuticals, specifically targeting central nervous system disorders. Its unique molecular structure allows it to interact with various biological targets, making it a promising candidate for the treatment of mood disorders and other neurological conditions.
Used in the Study of Central Nervous System Disorders:
In the field of neuroscience, 4-(4-Benzyl-piperazin-1-yl)-benzoic acid is employed as a compound of interest for understanding and potentially treating a range of neurological conditions. Its interaction with the central nervous system provides insights into the mechanisms underlying these disorders and aids in the development of targeted therapies.
Used in the Treatment of Mood Disorders:
4-(4-Benzyl-piperazin-1-yl)-benzoic acid is used as a potential therapeutic agent for mood disorders. Its ability to modulate neurotransmitter systems and influence the central nervous system makes it a candidate for the development of treatments aimed at alleviating the symptoms of such conditions.
Used in the Development of Neurological Condition Treatments:
In the realm of neurology, 4-(4-Benzyl-piperazin-1-yl)-benzoic acid is utilized in the research and development of treatments for various neurological conditions. Its potential to target specific pathways and receptors within the nervous system positions it as a valuable component in the creation of new therapeutic strategies.

InChI:InChI=1/C18H20N2O2/c21-18(22)16-6-8-17(9-7-16)20-12-10-19(11-13-20)14-15-4-2-1-3-5-15/h1-9H,10-14H2,(H,21,22)

Upstream product

• 90905-00-3 4-(4-benzylpiperazin-1-yl)benzonitrile 
• 100-52-7 benzaldehyde 
• 80518-57-6 ethyl 4-(piperazin-1-yl)benzoate 

Downstream Products

• 221360-92-5 (S)-N-[5-(4-Methylpiperazin-1-yl)-3,4-dihydro-2H-1-benzopyran-3-yl]-4-(4-benzylpiperazin-1-yl)benzamide 
• 197446-31-4 (R)-N-8-(4-Methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl-4-(4-benzylpiperazin-1-yl)benzamide 
• 1030830-21-7 C₂₉H₃₄N₄O₃ 
• 1092504-64-7 C₂₈H₃₂N₄O 
• 1092481-66-7 C₂₇H₂₆N₆ 
• 1422207-84-8 C₃₆H₄₂N₄O₂ 
• 1092481-67-8 C₂₀H₂₀N₆ 
• 1092480-71-1 C₃₂H₃₂Cl₂N₈O 
• 1092504-65-8 C₂₁H₂₆N₄O 
• 1092504-38-5 C₂₉H₃₀Cl₂N₄O₂ 
• 1092504-36-3 C₃₄H₄₀Cl₂N₆O₂ 

Relevant articles and documents

Base-Mediated Oxidative Degradation of Secondary Amides Derived from p-Amino Phenol to Primary Amides in Drug Molecules

One of the most common functional groups encountered in drug molecules is the amide, and the most common degradation pathway for amides is base-mediated hydrolysis to its constituent amine and carboxylic acid. Herein, we report for the first time, a base-

Benzamide nitriles

Compounds of the formula (I) wherein m, n, A, R1, R2, R3, R4, R5 and R6 are as described herein, together with methods for making the compounds and using the compounds for treatment of diseases or conditions mediated by Cathepsin K.

Substituted chroman derivatives

The present invention relates to new new piperidyl or piperazinyl-substituted dihydro-2H-1-benzopyran derivatives compound having the formula (I) wherein X is N or CH; Y is NR2CH2, CH2NR2, NR2CO, CONR

Substituted 1,2,3,4-tetrahydronaphthalene derivatives

PCT No. PCT/SE97/00469 Sec. 371 Date Apr. 25, 1997 Sec. 102(e) Date Apr. 25, 1997 PCT Filed Mar. 20, 1997 PCT Pub. No. WO97/34883 PCT Pub. Date Sep. 25, 1997New piperidinyl- or piperazinyl-substituted-1,2,3,4-tetrahydronaphthalene derivatives having the formula wherein X is N or CH; Y is NR2CH2, CH2-NR2, NR2-CO, CO-NR2 or NR2SO2; R1is H, C1-C6 alkyl or C3-C6 cycloalkyl; R3 is C1-C6 alkyl, C3-C6 cycloalkyl or (CH2)n-aryl, where aryl is phenyl or a heteroaromatic ring containing one or two heteroatoms selected from N, O and S and which may be mono- or di-substituted; n is 0-4; as (R)-enantiomer, (S)-enantiomer or a racemate in the form of the free base or a pharmaceutically acceptable salt or hydrate thereof; a pharmaceutical formulation containing the compounds, use of the compounds in the treatment of 5-hydroxytryptamine mediated disorders, processes for the preparation of the compounds and intermediates for the preparation of the compounds.